Life Sciences | Fieldfisher
Skip to main content
Select location

Why choose our Life Sciences lawyers?

Europe offers a world-class science base with a thriving ecosystem, which boasts a rich array of entities ranging from start-ups all the way up to some of the world's largest pharmaceutical companies.

During an unprecedented time of innovation, it is vital to have in place professional advisors that have the necessary capabilities to adapt just as rapidly and that can provide the right support and input exactly when and where it is needed.

Fieldfisher's focus on cross-departmental collaboration means that we are well placed to seamlessly provide multifaceted legal support. With a wealth of experience advising small and large entities alike, our expertise across key subsectors, including digital health, agrochemicals, cannabis and cell and gene therapy, means we deliver meaningful and impactful value to our clients.

Internationally, life sciences and healthcare remains a high priority sector for spending and investment in order to support growth and innovation at both a governmental and private financing level. Accordingly, it is critical for companies to pick the right advisors and here at Fieldfisher we are committed to delivering high-quality advice.

Fieldfisher is internationally recognised for its work in the regulatory environment and routinely advises on the implications of current and future regulation in the life sciences and healthcare industry. Continued technological and scientific advancement brings with it significant changes in both the regulatory and legislative landscape and forthcoming changes will require ongoing internal review and consultation in order to avoid avoidable complications and setbacks. 

Life Sciences Insights
Filter Media
Key numbers
23
numbers
25
laptops
100
cranes
How can we help you?
All sectors All services
Our team can help you across the following areas:
Agrochemicals
Cannabis
Cell and gene therapy
Healthcare
Pharmaceuticals and Biotechnology
Medical Devices
Copyright and Database Rights
Trade Marks and Brands
Arbitration
Corporate Disputes
Web 3.0 and Distributed Ledger Technology
Notable deals
Advised Ultromics, a leader in AI enabled cardiovascular imaging solutions, on its Series B funding round
Fieldfisher advised UK headquartered MedTech company Ultromics on its Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation, to help transform cardiac disease treatment.
Advising Roche Products Ltd on its contributions unlicensed medicines
Our Life Sciences team have continued to support oncology and ophthalmology medications, labelling Brexit and export control issues as the medical giant navigate new challenges.
What people say abut us....
Legal 500
Lorem ipsum odor amet, consectetuer adipiscing elit. Dictum imperdiet vivamus condimentum ad quis cubilia sodales quis. Condimentum facilisis potenti magnis nascetur id. Imperdiet consectetur ultricies hendrerit fringilla convallis commodo tellus. Ante primis class malesuada per at leo magna. Ut class tempus tempus; sollicitudin facilisi primis. Felis sem conubia congue varius mi. Urna fames class lacinia rhoncus erat senectus placerat. Nisl auctor convallis nascetur eu magnis class.
Chambers
Lorem ipsum odor amet, consectetuer adipiscing elit. Dictum imperdiet vivamus condimentum ad quis cubilia sodales quis. Condimentum facilisis potenti magnis nascetur id. Imperdiet consectetur ultricies hendrerit fringilla convallis commodo tellus. Ante primis class malesuada per at leo magna. Ut class tempus tempus; sollicitudin facilisi primis. Felis sem conubia congue varius mi. Urna fames class lacinia rhoncus erat senectus placerat. Nisl auctor convallis nascetur eu magnis class.Lorem ipsum odor amet, consectetuer adipiscing elit. Dictum imperdiet vivamus condimentum ad quis cubilia sodales quis. Condimentum facilisis potenti magnis nascetur id. Imperdiet consectetur ultricies hendrerit fringilla convallis commodo tellus. Ante primis class malesuada per at leo magna. Ut class tempus tempus; sollicitudin facilisi primis. Felis sem conubia congue varius mi. Urna fames class lacinia rhoncus erat senectus placerat. Nisl auctor convallis nascetur eu magnis class.
Key contacts
see full team

Fieldfisher Insights Hub

Subscribe Today!

Interested in recieving more updates about Life Sciences, use the link below to subscribe to the latest Fieldfisher legal insights. 

Subscribe now

Notable deals and highlights

  • Advising Roche Products Limited on its contributions unlicensed medicines for treatment for and help with management of the Covid-19 virus, including various aspects of the clinical trials processes. In addition to this, Our Life Sciences team have also continued to support oncology and ophthalmology medications, labelling Brexit and export control issues as the medical giant navigate new challenges. Our team also advised Roche Products on two research collaboration agreements.
  • Advised Ultromics, a leader in AI enabled cardiovascular imaging solutions, on its Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation, to help transform cardiac disease treatment. Fieldfisher advised UK headquartered MedTech company Ultromics, a leader in AI enabled cardiovascular imaging solutions, on its Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation, to help transform cardiac disease treatment.
  • We further advised Ultromics on complex contracts in relation to them winning a competition for a phase 3 and phase 4 grant sponsored by the NHS and related bodies to implement AI technology into the NHS and the deals generated a number of press articles:
  • Ultromics raises $33M in Series B funding to help transform cardiac disease treatment - Ultromics
  • Ultromics Raises $33M in Series B Funding to Help Transform Cardiac Disease Treatment (prnewswire.com)
  • Fieldfisher advises Ultromics on $33 million Series B funding | Fieldfisher
  •  Advised Synairgen in relation to a Phase III Clinical Trial for their interferon Beta therapeutic inhaled treatment for Covid-19. We advised Synairgen in relation to a Phase III Clinical Trial for their interferon Beta therapeutic inhaled treatment for covid-19, which completed on 10 February 2022. In addition to this, we also advised Synairgen on a major fundraising primarily intended to enable them to progress with the Phase III clinical trials, enrolling participants across multiple countries, and fund manufacturing and device scale-up activities. The transaction was one of largest public fundraisings in the biotech sector for several years and followed a £14 million fundraising Fieldfisher advised the company on in March 2020.

Latest Life Sciences news and views

view all insights
Get in touch
Hide
Submit your request
We advise on all aspects of the Health and Life Sciences sector,
Our Health & Life Sciences
Robin Spender
Partner, Banking and Finance
Robert Jappie
Partner
GB
AD
AE
AF
AG
AI
AL
AM
AN
AO
AQ
AR
AS
AT
AU
AW
AZ
BA
BB
BD
BE
BF
BG
BH
BI
BJ
BL
BM
BN
BO
BR
BS
BT
BW
BY
BZ
CA
CC
CD
CF
CG
CH
CI
CK
CL
CM
CN
CO
CR
CU
CV
CX
CY
CZ
DE
DJ
DK
DM
DO
DZ
EC
EE
EG
ER
ES
ET
FI
FJ
FK
FM
FO
FR
GA
GB
GD
GE
GF
GG
GH
GI
GL
GM
GN
GP
GQ
GR
GS
GT
GU
GW
GY
HK
HN
HR
HT
HU
ID
IE
IL
IM
IN
IO
IQ
IR
IS
IT
JE
JM
JO
JP
KE
KG
KH
KI
KM
KN
KP
KR
KW
KY
KZ
LA
LB
LC
LI
LK
LR
LS
LT
LU
LV
LY
MA
MC
MD
ME
MF
MG
MH
MK
ML
MM
MN
MO
MP
MQ
MR
MS
MT
MU
MV
MW
MX
MY
MZ
NA
NC
NE
NF
NG
NI
NL
NO
NP
NR
NU
NZ
OM
PA
PE
PF
PG
PH
PK
PL
PM
PN
PR
PS
PT
PW
PY
QA
RE
RO
RS
RU
RW
SA
SB
SC
SD
SE
SG
SH
SI
SJ
SK
SL
SM
SN
SO
SR
SS
ST
SV
SY
SZ
TC
TD
TG
TH
TJ
TK
TL
TM
TN
TO
TR
TT
TV
TW
TZ
UA
UG
US
UY
UZ
VA
VC
VE
VG
VI
VN
VU
WF
WS
YE
YT
ZA
ZM
ZW
US